Original language | English (US) |
---|---|
Pages (from-to) | 2141-2142 |
Number of pages | 2 |
Journal | Annals of Oncology |
Volume | 29 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2018 |
Funding
NIH Delaney AIDS Research Enterprise (DARE; AI096109 and UM1AI126611); NIH/NIAID R01AI122862 (TJH); NIH/NIAID K08AI116344 (EPS); Creative and Novel Ideas in HIV Research Program (CNIHR) through a supplement to the UCSF Center For AIDS Research funding (P30 AI027763) (EPS); This funding was made possible by collaborative efforts of the Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, and the International AIDS Society (EPS). The Foundation for AIDS Research (amfAR) Institute for HIV Cure Research. TJH receives grant support from Gilead Biosciences and consults for Merck and Co. All remaining authors have declared no conflicts of interest.
ASJC Scopus subject areas
- Hematology
- Oncology